Evogene (EVGN) Income from Continuing Operations (2012 - 2026)
Evogene (EVGN) posted Income from Continuing Operations of 5910000.0 for Q1 2026, down 10.86% sequentially from 5331000.0 in Q4 2025, and down 210.56% YoY from 5345403.99 in Q1 2025.
Evogene (EVGN) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Evogene has reported Income from Continuing Operations for 15 years, with the latest figure at 5910000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 210.56% year-over-year to 5910000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17497000.0 (down 43.18% YoY) and the FY2025 annual result came in at 13492000.0, up 8.94% from the prior year.
- Income from Continuing Operations slipped to 5910000.0 in Q1 2026 per EVGN's latest filing, from 5331000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 983000.0 in Q4 2024 and troughed at 9754000.0 in Q2 2022.
- A 5-year average of 5256470.59 and a median of 5331000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 113.4% in 2024, then sank 642.32% in 2025.
- Over 5 years, Income from Continuing Operations stood at 3821000.0 in 2022, then sank by 92.02% to 7337000.0 in 2023, then soared by 113.4% to 983000.0 in 2024, then tumbled by 642.32% to 5331000.0 in 2025, then slipped by 10.86% to 5910000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 5910000.0, 5331000.0, and 2728000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -5.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.91 Mn |
| Dec 31, 2025 | -5.33 Mn |
| Sep 30, 2025 | -2.73 Mn |
| Jun 30, 2025 | -3.53 Mn |
| Mar 31, 2025 | -1.90 Mn |
| Dec 31, 2024 | 983,000.00 |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | -4.55 Mn |
| Mar 31, 2024 | -3.85 Mn |
| Dec 31, 2023 | -7.34 Mn |
| Sep 30, 2023 | -3.86 Mn |
| Jun 30, 2023 | -7.78 Mn |
| Mar 31, 2023 | -6.98 Mn |
| Dec 31, 2022 | -3.82 Mn |
| Sep 30, 2022 | -7.16 Mn |
| Jun 30, 2022 | -9.75 Mn |
| Mar 31, 2022 | -9.11 Mn |
| Dec 31, 2021 | -8.08 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -6.90 Mn |